We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.
Keywords: Antiretroviral therapy; Coronavirus; Enzyme-linked immunosorbent assay (ELISA); Plaque reduction assay; Severe acute respiratory syndrome.
Copyright © 2021 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.